Research published in Stroke indicates that vaginal estrogen tablets are safe for postmenopausal women post-stroke, offering a viable option for managing menopausal symptoms without increasing stroke risk. Additionally, Creative Biogene's antibody purification platform provides high-yield, high-purity antibodies for various biotechnology applications, enhancing research capabilities.

Mainly Mozart has chosen Dr. Erica Ollmann Saphire, President and CEO of La Jolla Institute for Immunology, as the recipient of the 2025 San Diego Genius Award. Her groundbreaking research on viruses like Ebola and SARS-CoV-2 has been instrumental in global vaccine design efforts. In another collaboration, BioMed X and Novo Nordisk are working together to enhance oral peptide drug delivery, aiming to develop technologies for improved absorption of peptide-based therapeutics in the gut.

Ascentage Pharma initiates Phase III trial for Lisaftoclax in higher-risk MDS patients, University of Rochester develops material for solar thermoelectric generators, and Fathom Nickel Inc. completes summer field exploration program at Gochager Lake Project despite wildfire disruption.

Soligenix Inc. receives FDA Orphan Drug Designation for dusquetide in Behçet’s Disease, showcasing positive Phase 2a results. On the other hand, Creative Biolabs offers specialized antibody QC services and a scholarship program for students in biology and related fields, emphasizing innovation in antibody development.

Torr Metals Inc. announced high-grade copper discoveries at the Bertha Zone in British Columbia, showcasing significant mineralization and potential porphyry targets. Meanwhile, Soligenix Inc. is advancing a heat-stable ricin vaccine, RiVax(R), with promising efficacy and plans for pivotal animal studies to combat the deadly biothreat of ricin toxin.

A study in Pakistan highlighted the seismic vulnerability of non-engineered structures in Dir City, emphasizing the need for stricter regulations and retrofitting. In satellite navigation, a new method integrating inter-satellite link data with onboard observations significantly improves orbit determination precision. Additionally, a LEGO-like hydrogel system developed in Beijing enables reversible 3D information encoding, offering dynamic data storage and manipulation capabilities.

Maryland faces federal funding cuts in its science and engineering research sector, while states like Massachusetts propose support for research institutions. Lahontan Gold Corp. is advancing its Santa Fe Mine project in Nevada, BioCorRx Inc. reports substantial revenue growth driven by LUCEMYRA® sales, and Intensity Therapeutics revolutionizes cancer treatment with innovative approaches. Additionally, companies like Clene Inc. and Soligenix Inc. are making strides in biopharma with ALS therapy and treatments for rare diseases. Copper demand is soaring due to AI data-center construction, with Nicola Mining positioning itself to meet escalating industrial demand.

Creative Biolabs is a leading biotechnology company offering tailored liposomal drug delivery services to accelerate gene therapy research. With a focus on nucleic acid and prodrug loading, they provide customizable formulations for enhanced stability, release kinetics, and target specificity, all while maintaining regulatory compliance and global availability for research purposes.

Annovis Bio Inc. provided updates on their Phase 3 trial for early Alzheimer’s disease, with 76 secured U.S. sites and enrollment progressing as planned. The company presented at AAIC 2025, expanded global IP coverage, and reported cash and equivalents of $17.1 million as of June 30, 2025. Quarterly R&D expenses were $5.2 million, G&A expenses decreased to $1.1 million, and net loss per share narrowed to $0.32. Annovis Bio remains focused on neurodegenerative diseases like Alzheimer's and Parkinson's, aiming to enhance patient outcomes.

NRx Pharmaceuticals Inc. is making waves on Wall Street with its groundbreaking therapies for suicidal bipolar depression. With promising drugs like NRX-100 and NRX-101, along with strategic moves like Fast Track Designation and removing toxic preservatives from ketamine products, NRx is poised for success in the biopharmaceutical industry. With a focus on offering life-saving therapies through HOPE Therapeutics, NRx is a company with significant potential in the treatment of a widespread and impactful condition.